↓ Skip to main content

Dove Medical Press

Article Metrics

Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections

Overview of attention for article published in Infection and Drug Resistance, October 2013
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
71 Dimensions

Readers on

mendeley
81 Mendeley
Title
Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections
Published in
Infection and Drug Resistance, October 2013
DOI 10.2147/idr.s51340
Pubmed ID
Authors

Alessandro Pasqualotto, Diego Rodrigues Falci

Abstract

The triazole class of antifungal drugs comprises first-line agents for the treatment of several invasive fungal diseases. Isavuconazole is a novel broad-spectrum triazole agent. Here we summarize its characteristics and compare it with the currently available antifungal agents. Isavuconazole is administered as a prodrug, and it is water soluble. Oral and intravenous formulations are available. Its intravenous formulation does not contain cyclodextrin, which is an advantage over voriconazole, considering the potential for nephrotoxicity of cyclodextrin. As with other azoles, isavuconazole requires a loading dose. Due to its prolonged half-life, a once-a-day regimen is possible. Considering that isavuconazole shares the same mechanism of action with the other triazoles, cross-resistance is an important concern in the class. Tolerability and safety profiles are favorable, and no serious adverse events have been consistently reported. Significant interactions with drugs metabolized by cytochrome P450 are expected to occur, especially with substrates and inducers of the CYP3A4 enzyme. Isavuconazole has in vitro activity against most medically important fungi, including species of Candida, Aspergillus, and Cryptococcus. It has some activity against the agents of mucormycosis. Clinical data regarding isavuconazole remain limited because ongoing trials have not yet been completed or published. Isavuconazole has the potential to become first-line therapy for invasive aspergillosis. It also has the potential for use in the context of antifungal prophylaxis, salvage therapy, or in combination regimens. Results of clinical trials are ultimately expected in order to adequately position isavuconazole in the current antifungal armamentarium.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 81 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Japan 1 1%
United Kingdom 1 1%
United States 1 1%
Denmark 1 1%
Unknown 77 95%

Demographic breakdown

Readers by professional status Count As %
Other 13 16%
Researcher 12 15%
Student > Master 11 14%
Student > Bachelor 8 10%
Student > Ph. D. Student 8 10%
Other 20 25%
Unknown 9 11%
Readers by discipline Count As %
Medicine and Dentistry 32 40%
Agricultural and Biological Sciences 13 16%
Biochemistry, Genetics and Molecular Biology 6 7%
Chemistry 5 6%
Pharmacology, Toxicology and Pharmaceutical Science 5 6%
Other 8 10%
Unknown 12 15%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 May 2018.
All research outputs
#7,712,322
of 12,923,750 outputs
Outputs from Infection and Drug Resistance
#158
of 405 outputs
Outputs of similar age
#88,725
of 180,425 outputs
Outputs of similar age from Infection and Drug Resistance
#6
of 6 outputs
Altmetric has tracked 12,923,750 research outputs across all sources so far. This one is in the 39th percentile – i.e., 39% of other outputs scored the same or lower than it.
So far Altmetric has tracked 405 research outputs from this source. They receive a mean Attention Score of 4.4. This one has gotten more attention than average, scoring higher than 60% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 180,425 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 49th percentile – i.e., 49% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one.